We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Outline
- Manufacturing requirements
- Manufacturing overview
- Upstream process development
- Downstream process development: Harvest and clarification
- Downstream process development: Capture chromatography and additional purification
- Analytical considerations
- Viral genome titer
- Potency
- Capsid titer
- Particle content
- Comparability assessment
- Introduction: Comparability assessment
- Evaluation of analytical comparability results
- Key regulatory guidance on comparability
- High level summary of the statistical methods
- Equivalence test: Sample size driven EAC is more suitable for GTx
- Example using simulated comparability data
- Summary of three statistical methods
- Summary
- Financial disclosures
Topics Covered
- Manufacturing process overview
- Development and challenges in manufacturing process
- Analytical considerations: critical quality attributes and challenges
- Comparability assessment
- Evaluation of analytical comparability results
- Key regulatory guidance on comparability
- Summary of statistical methods
- Equivalence test
Links
Categories:
External Links
Talk Citation
Sloan, C. and Cheng, A. (2026, June 30). rAAV gene therapy: manufacturing, analysis & comparability [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved July 1, 2026, from https://doi.org/10.69645/ZGVH5397.Export Citation (RIS)
Publication History
- Published on June 30, 2026
Financial Disclosures
- No commercial/financial matters to disclose.
- No commercial/financial matters to disclose.
A selection of talks on Pharmaceutical Sciences
Transcript
Please wait while the transcript is being prepared...
0:00
Hello. My name is
Dr. Courtney Sloan,
and I'm a Senior Principal
Scientist at Pfizer,
actually located in the Midwest,
and I've spent the last
seven years working
on our gene therapy products.
So I'll begin our topic,
Adeno-associated
virus gene therapy
challenges in manufacturing
and analytical processes.
I will then hand over
the talk to Dr. Cheng
for a discussion on
establishing comparability
when these processes change.
0:30
As the outline here for
this talk suggests,
I'll begin our topic with
a manufacturing process overview
highlighting the main
areas for development,
optimization and challenges from
upstream proceeding through
downstream purification.
Following that,
we'll transition to
a discussion on the
challenges in developing
for main analytical assays,
for critical quality
attributes unique to
gene therapies and
a discussion on
establishing comparability
when these processes change.
1:03
Adeno-associated
virus manufacturing
at the highest level has
three main requirements,
the production of AAV
Cap and Rep genes,
the production of the
therapeutic gene of interest,
which is flanked by
ITRs on either end,
as well as helper genes.
Various challenges
exist throughout
this manufacturing process,
from the choice of cell line,
manufacturing platform,
through the subsequent
purification steps.
Many of these process
components are capsid serotype,
and even at times,
trans gene dependent.
1:37
Manufacturing options within
the AAV space are still
rather diverse, with
both transient and
stable or hybrid cell
banks available for use.
The most commonly
implemented at this time is
the HEK293 cells
transfected with plasmids,
and for the subsequent discussion,
this will be the focus.
By far, the largest challenge to